TICKERNERD
Menu
ORKAORKAHealthcare · Biotechnology

ORKA Stock Forecast: Oruka Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$80
−1.24% on the day

The 13 Wall Street analysts covering Oruka Therapeutics, Inc. hold a median 12-month price target of $156 — +94.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 24 Oct 2026 — in the lower half.

Market cap
$5.3B
Ticker Nerd rank
40/ 100
Median analyst target
$156
Analysts covering
13
Revenue$0.0
Operating income−$50.1M
Net income−$41.2M
Free cash flow−$33.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.4%
1M
−10.9%
YTD
+164.4%
1Y
+195.4%
From 52W high
−29.1%
From 52W low
+206.0%
$26
$113
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ORKA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Oruka Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
40/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Value
80
Volatility
80
Quality
62
Growth
42
Revisions
33
Accruals
23
Issuance
22
Size
22

Momentum (91): The shares have been drifting up relative to others.

Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.

Size (22): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ORKA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ORKA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150$200Jan 26Apr 26Jul 26Oct 26ORKAHigh $200Median $156Low $117

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
13 Buy0 Hold0 Sell
Low $117Median $156High $200

The green dot is the last close — the median target sits +94.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Oct 2026BTIGReiteratesBuy$151
24 Sept 2026HC Wainwright & Co.ReiteratesBuy—
24 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
24 Sept 2026WedbushReiteratesOutperform—
24 Sept 2026WedbushReiteratesOutperform$165
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
3 Sept 2026HC Wainwright & Co.ReiteratesBuy—
11 Aug 2026BTIGReiteratesBuy$151
11 Aug 2026BTIGReiteratesBuy—
11 Aug 2026GuggenheimReiteratesBuy$200
11 Aug 2026GuggenheimReiteratesBuy—
11 Aug 2026WedbushReiteratesOutperform$165
11 Aug 2026WedbushReiteratesOutperform—
3 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$120
13 July 2026BTIGReiteratesBuy$151
13 July 2026BTIGReiteratesBuy—
1 July 2026UBSMaintainsBuy—
23 June 2026HC Wainwright & Co.ReiteratesBuy—
18 May 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ORKA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

ORKA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Oruka Therapeutics, Inc. returned +195.4% against +14.3% for the S&P 500, dividends included.

ORKA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26ORKAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ORKA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
8
Fundamentals

Oruka Therapeutics, Inc. (ORKA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−43.3×

Cheaper than 98% of US stocks

Price / sales
—
Price / book
4.4×

Cheaper than 22% of US stocks

EV / EBITDA
−28.6×

Cheaper than 92% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−18.2%

Higher than 32% of US stocks

Return on assets
−13.0%

Higher than 24% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Oruka Therapeutics, Inc. (ORKA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Oruka Therapeutics, Inc. has a market value of $5.3B and an enterprise value of $4.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$132.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$101.2M.

  • Shares outstanding: 61.1M.

  • Trailing P/E: −43.3×; forward P/E: −28.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Oruka Therapeutics, Inc. employs 68 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Oct 2026

Data provided by Twelve Data

Peers

ORKA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ORKAOruka Therapeutics, Inc.$5.3B40
COGTCogent Biosciences, Inc.$5.3B31
KODKodiak Sciences, Inc.$5.3B49
MIRMMirum Pharmaceuticals, Inc.$5.2B67
CGONCG Oncology, Inc.$5.4B17
SRRKScholar Rock Holding Corp.$5.1B26
PTCTPTC Therapeutics, Inc.$5.0B61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Oruka Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ORKA news & analysis

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026

GlobeNewsWire · 25 Oct 2026neutral

Oruka Therapeutics announced that it will report Week 16 data from the ongoing EVERLAST-B Phase 2b trial of ORKA-001 in moderate-to-severe plaque psoriasis on October 26, 2026. The company will discuss the results on a conference call and webcast at 8:00 a.m. ET.

Why it matters — The update will provide information on the clinical trial progress of ORKA-001, a program Oruka is developing for plaque psoriasis.

Oruka Therapeutics: The Psoriasis Market Is Becoming A Barbell, And ORKA-001 Owns The Far End

Seeking Alpha · 18 Oct 2026positive

Seeking Alpha describes Oruka as a leader in ultra-long-acting psoriasis injections, citing ORKA-001’s PASI 100 and PASI 90 results at Week 28 and a replicated response in the crossover cohort. It also highlights the company’s $1.1 billion cash balance, Hypercon technology license and pipeline breadth.

Why it matters — The reported efficacy and financial resources are relevant to watchers assessing ORKA-001’s clinical profile and the company’s capacity to fund development through BLA.

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

Zacks Investment Research · 24 Sept 2026negative

Oruka Therapeutics' ORKA-001 showed deeper psoriasis clearance at week 28 in efficacy data, but the company's shares fell 5% as safety disclosures weighed on investor sentiment despite the positive results.

Why it matters — A Oruka watcher would care because week 28 efficacy and safety data for its lead candidate ORKA-001 directly informs the drug's development outlook and near-term share price moves.

Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy

Benzinga · 23 Sept 2026positive

Oruka Therapeutics reported positive week 28 results from its Phase 2a clinical trial of ORKA-001 for moderate-to-severe plaque psoriasis, indicating deepening efficacy of the drug.

Why it matters — Positive week 28 data suggests the company's lead psoriasis candidate continues to demonstrate durable and improving clinical efficacy.

Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

GlobeNewsWire · 23 Sept 2026positive

Oruka Therapeutics announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. Despite no dosing after Week 4, PASI 100 rose to 71.4% and PASI 90 to 87.3%, placebo crossover patients reached similar rates, and ORKA-001 maintained a favorable safety and tolerability profile through Week 28.

Why it matters — The data indicate sustained and deepening efficacy from a single early dosing period, supporting ORKA-001's potential as a half-life extended psoriasis therapy ahead of additional 16-week and 52-week readouts expected in 2026.

FAQ

Frequently asked questions about ORKA stock

What is the ORKA stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Oruka Therapeutics, Inc. have a median 12-month price target of $156, with estimates ranging from $117 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ORKA stock a buy right now?

Of the 13 analysts covering Oruka Therapeutics, Inc., 13 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Oruka Therapeutics, Inc. 40 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ORKA?

As at 24 Oct 2026, Oruka Therapeutics, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will ORKA stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +94.0% from the last close, and Ticker Nerd's factor model ranks Oruka Therapeutics, Inc. 40 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ORKA stock forecast for 2030?

No analyst covering Oruka Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORKA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $117 to $200 over the next 12 months.

How has ORKA stock performed over the past year?

Oruka Therapeutics, Inc. returned +195.4% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Oruka Therapeutics, Inc. do?

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions.

What is the latest news on ORKA?

The most recent item we track (GlobeNewsWire, 25 Oct 2026): "Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026". Oruka Therapeutics announced that it will report Week 16 data from the ongoing EVERLAST-B Phase 2b trial of ORKA-001 in moderate-to-severe plaque psoriasis on October 26, 2026. The company will discuss the results on a conference call and webcast at 8:00 a.m. ET.

Company

About Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions. Its current pipeline centers on treatments designed to target key pathways involved in immune-mediated skin and joint diseases, including plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa. The company’s lead programs include ORKA-001, which targets the interleukin-23 p19 subunit, and ORKA-002, which targets interleukin-17A and interleukin-17F. Oruka Therapeutics is also advancing additional programs and combination regimens intended to broaden its dermatology and immunology portfolio. Headquartered in Menlo Park, California, Oruka Therapeutics plays a role in the biotech sector by developing targeted biologic medicines for chronic inflammatory diseases.

CEO Dr. Lawrence Otto Klein Ph.D. · 68 employees · United States · https://orukatx.com